Skip to main content
Premium Trial:

Request an Annual Quote

Lion s Preliminary Q3 Revenues and Losses Down; New Revenue Accounting Practice

NEW YORK, Feb. 4 (GenomeWeb News) - Lion Bioscience yesterday reported preliminary earnings for the third quarter of its current fiscal year, which ended Dec. 31. The results reflect a change in its revenue accounting practice.


The company expects revenues of 6 million ($7.5 million) for the quarter, down from €8.5 million the year before. Its net loss is expected to be 6.1 million, down from 22 million for the same period last year.


As of Dec. 31, Lion had cash, cash equivalents, and marketable securities of 48.1 million.


Under its new accounting practice, Lion will recognize revenue from software licenses ratably over the term of the contract, rather than upon delivery of the software. Lion is planning to restate its result for prior fiscal years accordingly.


As a result of the change, the company expects to see increased revenues for the current fiscal year, and reduced revenues for prior years. Lion plans to issue its nine-month report for the current fiscal year at the end of the month.


The company said it no longer expects to reach its goal of break-even this quarter. Its guidance for the next fiscal year will rely on whether or not Bayer will extend its collaboration with Lion, scheduled to end this summer. "The on-going slump in the life science informatics market, the weak U.S. dollar as well as a slower than anticipated market introduction of new products, continue to have an adverse effect on Lion's business," Lion stated.



The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.